The role of metabolic syndrome variant in the malignant tumors progression

Natalia V Yunusova¹, Irina V Kondakova², Larisa A Kolomiets³, Sergey G Afanas'ev⁴, Anastasia Yu Kishkina², Liudmila V Spirina⁵

Affiliations

¹ Laboratory of tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, 634009, Tomsk, Kooperativny str., 5, Russia; Biochemistry Division, Siberian State Medical University, 634050, Tоmsk, Moskovskiy str. 2., Russia.
² Laboratory of tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, 634009, Tomsk, Kooperativny str., 5, Russia.
³ Department of Oncogynecology, Cancer Research Institute, Тomsk National Research Medical Center, Russian Academy of Science, 634009, Tomsk, Kooperativny str., 5, Russia; Oncology Division, Siberian State Medical University, 634050, Tоmsk, Moskovskiy str. 2., Russia.
⁴ Abdominal Oncology Department, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, 634009, Tomsk, Kooperativny str., 5, Russia; 2 - Siberian State Medical University, 634050, Tоmsk, Moskovskiy str. 2., Russia.
⁵ Laboratory of tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, 634009, Tomsk, Kooperativny str., 5, Russia; Biochemistry Division, Siberian State Medical University, 634050, Tоmsk, Moskovskiy str. 2., Russia. Electronic address: Spirinalv@oncology.tomsk.ru.

PMID: 29699953
DOI: 10.1016/j.dsx.2018.04.028

Review

The role of metabolic syndrome variant in the malignant tumors progression

Natalia V Yunusova et al. Diabetes Metab Syndr. 2018 Sep.

. 2018 Sep;12(5):807-812.

doi: 10.1016/j.dsx.2018.04.028. Epub 2018 Apr 17.

Authors

Natalia V Yunusova¹, Irina V Kondakova², Larisa A Kolomiets³, Sergey G Afanas'ev⁴, Anastasia Yu Kishkina², Liudmila V Spirina⁵

Affiliations

¹ Laboratory of tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, 634009, Tomsk, Kooperativny str., 5, Russia; Biochemistry Division, Siberian State Medical University, 634050, Tоmsk, Moskovskiy str. 2., Russia.
² Laboratory of tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, 634009, Tomsk, Kooperativny str., 5, Russia.
³ Department of Oncogynecology, Cancer Research Institute, Тomsk National Research Medical Center, Russian Academy of Science, 634009, Tomsk, Kooperativny str., 5, Russia; Oncology Division, Siberian State Medical University, 634050, Tоmsk, Moskovskiy str. 2., Russia.
⁴ Abdominal Oncology Department, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, 634009, Tomsk, Kooperativny str., 5, Russia; 2 - Siberian State Medical University, 634050, Tоmsk, Moskovskiy str. 2., Russia.
⁵ Laboratory of tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science, 634009, Tomsk, Kooperativny str., 5, Russia; Biochemistry Division, Siberian State Medical University, 634050, Tоmsk, Moskovskiy str. 2., Russia. Electronic address: Spirinalv@oncology.tomsk.ru.

PMID: 29699953
DOI: 10.1016/j.dsx.2018.04.028

Abstract

Metabolic syndrome (MS) is one of the leading risk factors for the development of some common cancers (endometrial cancer, postmenopausal breast cancer, colorectal cancer). Currently, a drug-induced metabolic syndrome related with androgen deprivation therapy in patients with prostate cancer represents a serious medical problem. Not only MS, or its individual components, but MS variants with different levels of leptin, adiponectin, visfatin, resistin are associated with tumor invasion, metastasis and survival rates in patients with MS-associated malignancies.

Keywords: Cancer; Drug-induced metabolic syndrome; Metabolic syndrome.

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The role of metabolic syndrome variant in the malignant tumors progression

Affiliations

The role of metabolic syndrome variant in the malignant tumors progression

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical